This is in line with the most recent report from SEER, although the U.S. survival rates were higher (94.8% for HR+/HER2– BC, 91% for HR+/HER2+ BC, 85.6% for HR-/HER2+ BC, and 77.6% for TNBC) (20). The gene discussed is ERBB2; the disease is breast cancer.